Clinical-stage biopharmaceutical developer of therapies for difficult-to-treat cancers; lead investigational GSK-3β inhibitor elraglusib targets NF‑κB and DNA damage response pathways. Elraglusib may also modulate anti-tumor immunity by regulating immune checkpoints and immune cell function.